Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1901 in Advanced Malignant Tumors
NCT05193721Phase 1Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-1901 in cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Adverse Events, Dose-Limiting Toxicity and 2 more. Started Feb 2022; status: completed.
02
Drugs
SHR-1901
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05193721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193721.